OmniAb (OABI)
NASDAQ:OABI
Want to see OABI full AI Analyst Report?
OABI Stock Chart & Stats
$1.64
-$0.06(-1.65%)
At close: 4:00 PM EST
$1.64
-$0.06(-1.65%)
Day’s Range― - ―
52-Week Range$1.22 - $2.30
Previous CloseN/A
Volume80.31K
Average Volume (3M)561.73K
Market Cap
$214.28M
Enterprise Value$171.23M
Total Cash (Recent Filing)$54.02M
Total Debt (Recent Filing)$20.33M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 07, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding144,782,650
10 Day Avg. Volume481,153
30 Day Avg. Volume561,725
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)0.79
Price to Sales (P/S)11.26
P/FCF Ratio-5.68
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue9.17
Enterprise Value/Gross Profit12.49
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$7.67Price Target Upside367.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$27.89M
Bulls Say, Bears Say
Bulls Say
Cash Position And Cost DisciplineReported cash position combined with cost-reduction measures, including workforce reductions, reduces immediate financing risk and strengthens operational discipline.
Partnerships And Milestone PotentialExpansion of partner and program metrics increases potential for future milestone payments and royalty income as collaborations progress toward commercial milestones.
Platform-driven Discovery RevenueLaunch of the OmniUltra discovery platform broadens partner interest by enabling discovery of human-like ultralong antibodies, supporting growth in discovery services revenue.
Bears Say
Earnings And Expectation ShortfallsReported quarterly and full-year results missed analyst expectations, highlighting near-term revenue and profitability pressure that could weigh on the stock.
Liquidity And Cash Burn ConcernsConstrained liquidity and ongoing cash burn keep reducing cash usage and improving operational efficiency as top strategic priorities to avoid potential financing needs.
Revenue Volatility From Irregular PaymentsDependence on irregular milestone and licensing payments causes topline volatility and uncertainty in forecasting sustainable revenue streams.
OmniAb News
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.22 and its highest was $2.29 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $214.28M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is May 07, 2026 which is in 16 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Mar 04, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.022.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.1.
How many shares outstanding does OmniAb have?
OmniAb has 144,782,650 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went up 10.497%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OmniAb Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (367.48% Upside)
$7.67 (367.48% Upside)
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.21%
12-Months-Change
Fundamentals
Return on Equity
-22.37%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
OmniAb
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
OABI Company Deck
OABI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong strategic and operational positives — accelerated partner and program additions, multiple platform launches (OmniUltra and xPloration), significant contracted milestone backlog (> $3B) and demonstrated cost discipline — all of which support a path toward royalty-driven recurring revenue. Offsetting risks include meaningful year‑over‑year revenue declines in 2025, continued net losses, program attrition, nascent instrument-based revenue today, and milestone timing uncertainty that prevents a precise breakeven timetable. On balance the momentum in partner/program growth, new technologies and sizable contracted milestones outweigh the nearer-term financial softness and timing risks.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$7.67
▲(367.48% Upside)
Technical Analysis
Cartesian Therapeutics
―
Tiziana Life Sciences
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
5.77% Insiders
9.98% Mutual Funds
0.06% Other Institutional Investors
76.28% Public Companies and
Individual Investors